“Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP TAZ) Lotion in Patients With Baseline Body Surface Area of 6 -12%”. 2020. SKIN The Journal of Cutaneous Medicine 4 (5): s37. https://doi.org/10.25251/skin.4.supp.37.